/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
Event: ESC Congress 2024
Topic: Antiplatelet Drugs
Session: Pharmacogenomics, cardio-omics, and cardiovascular drugs
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
Event: ESC Congress 2024
Topic: Antiplatelet Drugs
Session: Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Event: ESC Congress 2023
Topic: Anticoagulants
Session: Antithrombotic therapy in acute coronary syndromes and PCI
Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study
Event: ESC Congress 2023
Topic: Antiplatelet Drugs
Session: Antithrombotic therapy in acute coronary syndromes and PCI
Factor XI inhibitors in early clinical trials: a meta-analysis
Event: ESC Congress 2023
Topic: Anticoagulants
Session: Oral anticoagulation: minimising bleeding
Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease
Event: ESC Congress 2023
Topic: Antiplatelet Drugs
Session: Current and novel antiplatelet therapy in cardiovascular disease
Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis
Event: ESC Congress 2022
Topic: Coronary Arteries
Session: Epidemiology and artificial intelligence
Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease
Event: ESC Congress 2021 - The Digital Experience
Topic: Antiplatelet Drugs
Session: Congress committee e-posters choice in pharmacology and pharmacotherapy
